Erratum: The prescribing cascade revisited (The Lancet (2017) 389(10081) (1778–1780) (S0140673617311881) (10.1016/S0140-6736(17)31188-1));The prescribing cascade revisited

The Lancet

Volumn 389, Issue 10081, 2017, Pages 1778-1780

  Rochon, Paula A ^a,b   Gurwitz, Jerry H ^c,d  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION; DIAGNOSTIC ERROR; HUMAN; PRESCRIPTION;

DIAGNOSTIC ERRORS; DRUG PRESCRIPTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS;

EID: 85019083238     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31315-6     Document Type: Erratum

References (12)

1. 1 Rochon, PA, Gurwitz, JH, Drug therapy. Lancet 346 (1995), 32–36.
2. 2 Rochon, PA, Gurwitz, JH, Optimising drug treatment for elderly people: the prescribing cascade. BMJ 315 (1997), 1096–1099.
3. 3 Gurwitz, JH, Avorn, J, Bohn, RL, Glynn, RJ, Monane, M, Mogun, H, Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 272 (1994), 781–786.
4. 4 Canadian Institute for Health Information. Adverse drug reaction-related hospitalizations among seniors, 2006 to 2011. https://secure.cihi.ca/free_products/Hospitalizations%20for%20ADR-ENweb.pdf, March, 2013 (accessed April 20, 2017).
5. 5 Duerden, M, Avery, T, Payne, R, Polypharmacy and medicines optimisation: making it safe and sound. 2013. The King's Fund. https://www.kingsfund.org.uk/sites/files/kf/field/field_publication_file/polypharmacy-and-medicines-optimisation-kingsfund-nov13.pdf (accessed April 20, 2017).
6. 6 Scott, IA, Hilmer, SN, Reeve, E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 175 (2015), 827–834.
7. 7 Greater Manchester Shared Services, National Health Service. Polypharmacy: a deprescribing Toolkit. Version 1.0. May, 2016. Greater Manchester Medicines Management Group. http://gmmmg.nhs.uk/docs/guidance/NWCSU-Polypharmacy-guidance-2016.pdf (accessed April 20, 2017).
8. 8 Choosing Wisely Australia. 5 things clinicians and consumers should question. Developed by the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. http://www.choosingwisely.org.au/getmedia/e97bde53-e89c-4f4f-8380-5c9b3ff2da9f/CW_Recommendations_ASCEPT_v2.pdf.aspx, August, 2016 (accessed April 20, 2017).
9. 9 Gill, SS, Mamdani, M, Naglie, G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med 165 (2005), 808–813.
10. 10 Ball, R, Robb, M, Anderson, SA, Dal Pan, G, The FDA's sentinel initiative— a comprehensive approach to medical product surveillance. Clin Pharmacol Ther 99 (2016), 265–268.
11. 11 Rosenberg, J, Rochon, PA, Gill, SS, Unveiling a prescribing cascade in an older man. J Am Geriatr Soc 62 (2014), 580–581.
12. 12 Gill, SS, Anderson, GM, Fischer, HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 169 (2009), 867–873.